4.1c Composition of EN: Glutamine Systematic Review March 20214.1c Composition of EN: Glutamine

Question:

Compared to standard care, does glutamine-supplemented enteral nutrition result in improved clinical outcomes in critically ill patients?

Summary of Evidence: There were 13 level 2 studies and 3 level 1 studies, 5 of which were in burn patients (Garrel 2003, Zhou 2003, Peng 2004, Pattanshetti 2009, lamsirisaengthong 2017), 3 in trauma patients (Houdijk 1998, Brantley 2000 and McQuiggan 2008), 1 in elective cardiac surgery patients (Efremov 2017) and the remaining 7 were in mixed ICU patients. One study of mixed ICU patients also reported on the subgroup of trauma patients (van Zanten 2014).

Mortality: When the data from all the 11 trials that reported on 28 day or hospital mortality were aggregated, there was no statistically significant difference in overall hospital mortality between the groups receiving glutamine supplemented EN or not (RR 1.00. 95% CI 0.77, 1.30, p=1.00, test for heterogeneity $l^2 = 0\%$) (figure 1). Subgroup analyses of the 4 studies of trauma patients showed that glutamine supplemented EN had no significant effect on hospital mortality (RR 1.03, 95% CI 0.54, 1.97, p = 0.92, test for heterogeneity $l^2 = 0\%$) (figure 2). In the 4 studies of burn patients, patient deaths in hospital were reported in 3 studies (Garrel 2003, Pattanshetti 2009, lamsirisaungthong 2017) and a significant reduction in hospital mortality was associated with the use of enteral glutamine (RR 0.26, 95% CI 0.08, 0.80, p =0.02, test for heterogeneity $l^2 = 0\%$) (figure 3).

Infections: Of the 2 level 2 studies and 2 level 1 studies that reported on the total number of patients with infectious complications, there was no statistically significant difference in infectious complications with glutamine supplemented EN (RR 0.93, 95% CI 0.79, 1.10, p = 0.39, test for heterogeneity $l^2 = 0\%$) (figure 4). In the one study in burn patients that reported on patients with infections (Zhou 2003), glutamine supplemented EN was associated with a significant reduction in infectious complications while in one burn study (Garrel 2003) a significant reduction was seen in the number of positive blood cultures. In the subgroup of trauma patients, based on two studies, there was a trend towards a reduction in infections in the groups that received enteral glutamine (RR 0.85, 95% CI 0.68, 1.06, p = 0.15, test for heterogeneity $l^2 = 0\%$) (figure 5). In one study in mixed ICU patients, there were no statistically significant differences in the incidence of new severe sepsis between the EN glutamine supplemented group (5.6%, 95% CI; 0–13.9%) and the control group (11.8%, 95% CI, 2.8–23.5%; p = 0.309, Shariatpanahi 2019).

Length of Stay: There were 8 level 2 studies and 1 level 1 study that demonstrated a significant reduction in hospital length of stay (LOS) [WMD (weighted mean difference) -4.13, 95% CI -6.95, -1.30, p = 0.004, test for heterogeneity $l^2 = 41\%$] (figure 6). A stronger effect was seen in the subgroup of burn patients (WMD -8.18, 95% CI -12.69, -3.67, p = 0.0004, test for heterogeneity $l^2 = 30\%$) (figure 7) but not seen in the subgroup of trauma patients (WMD -0.54 95% CI -4.40, 3.31, p = 0.78, test for heterogeneity $l^2 = 0\%$) (figure 8). Enteral glutamine has no effect on ICU LOS (WMD -0.33, 95% CI -2.26, 1.60, p =0.74, test for heterogeneity $l^2 = 69\%$) (figure 9) when

all studies were aggregated but was associated with a trend towards a reduction in the subgroup of trauma patients from two studies (WMD -4.66, 95% CI -9.68, 0.36, p = 0.07, test for heterogeneity I²= 0%) (figure 10).

Mechanical ventilation: Only 4 studies, including one in burn patients (Garrel 2003) reported on mechanical ventilation as means and standard deviation and when the data were aggregated, enteral glutamine had no effect on duration of mechanical ventilation (WMD -0.19, 95% CI -0.89, 0.51, p =0.60, test for heterogeneity I² =0% (figure 11).

Conclusions:

1) Glutamine supplemented enteral nutrition is associated with a reduction in mortality in burn patients, but inconclusive in other critically ill patients.

2) Glutamine supplemented enteral nutrition may be associated with a reduction in infectious complications in burn and trauma patients.

3) Glutamine supplemented enteral nutrition is associated with a reduction in hospital length of stay in burn and other critically ill patients but not in trauma patients and may be associated with a reduction in ICU LOS in trauma patients.

4) Glutamine supplemented enteral nutrition has no effect on duration of mechanical ventilation in critically ill patients.

Level 1 study: if all of the following are fulfilled: concealed randomization, blinded outcome adjudication and an intention to treat analysis. Level 2 study: If any one of the above characteristics are unfulfilled

March 2021

Table 1. Randomized studies evaluating glutamine (EN) in critically ill patients

Study	Population	Methods	Intervention	Mortality		Infection	is # (%)‡	Hospital s	tay (days)	ICU LO	S (days)
		(score)	-Dose (gm/kg/day) or gm/day -Type of feeding	Experimental	Control	Experimental	Control	Experimental	Control	Experimenta	Control
1) Houdijk 1998	Critically ill trauma (100%) N = 80	C.Random: Yes ITT: No Blinding: Yes (10) Level: 2	 > 0.25 Altira Q (glutamine enriched formula) vs. isonitrogenous control (added amino acids) Same volume of feeding received in both groups 	4/41 (9.8)	3/39 (7.7)	20/35 (57.1)	26/37 (70.2)	32.7±17.1 (35)	33.0± 23.8 (37)	NA	NA
2) Jones 1999	Mixed ICU Population (6 burns, 6 trauma, no subgroup analysis) N = 78	C.Random: Yes ITT: No Blinding: Yes (8) Level: 2	0.16 Protina MP + Glutamine (10-15 gm Nitrogen/day) vs. Isonitrogenous Control (11-14 gm Nitrogen/day)	Hospital 10/26 (38.5) ICU 9/26 (35) 6 month 12/26 (46)	Hospital 9/24 (37.5) ICU 9/24 (38) 6 month 10/24 (42)	NA	NA	NA	NA	11 (4–54)	16.5 (5–66)
3) Brantley 2000	Critically ill trauma (100%) N = 72	C.Random: Not sure ITT: No Blinding: No (4) Level: 2	0.50 Glutamine supplemented Enteral formula vs. standard formula (Isonitrogenous) Protein given 1.5gm/kg/d	NA	NA	NA	NA	19.5±8.8 (31)	20.8±11.5 (41)	11.4	11.1
4) Hall 2003	Mixed ICU Population (mostly trauma, 7 burns) N = 363	C.Random: yes ITT: Yes Blinding: double (13) Level: 1	0.27 Isocal + glutamine (66 gms protein/day) vs. isonitrogenous formula, Isocal + glycine (64 gms protein/day)	6 months 27/179 (15) 30 days 26/179 (15) ICU 16/179 (9) Hospital 24/179 (13)	6 months 30/184 (16) 30 days 25/184 (14) ICU 14/184 (8) Hospital 23/184 (13)	38/179 (21)	43/184 (23)	25 (16-42)*	30 (19-45)*; p=NS	11(7-19) (excluding deaths)	13 (8-19) (excluding deaths)
	Trauma subgroup			7/76 (9)	6/78 (8)	Sepsis 7/76 (9)	Sepsis 11/78 (14)	NA	NA	NA	NA
5) Garrel 2003	Burns N = 45	C.Random: yes ITT: yes Blinding: double (11) Level: 1	0.28 Sandosource + glutamine (2.15 gm/kg/d protein) vs. Sandosource + amino acids (isonitrogenous), 1.97 gm/kg/day protein	2/21 (10)	12/24 (50)	Positive blood cultures 7/19 (37)	Positive blood cultures 10/22 (45)	33 ±17 (16) **	29 ±17 (19) **	NA	NA
6) Zhou 2003	Severe Burns TSBA 50-80 % N = 41	C.Random: yes ITT: no Blinding: double (8) Level: 2	0.35 Ensure + glutamine vs. Ensure + amino acids (isonitrogenous)	NA	NA	2/20 (10)	6/20 (30)	67 ± 4 (20)	73 ± 6 (20)	NA	NA

7) Peng 2004	Severe Burns TBSA > 30 % N = 48	C.Random: Not sure ITT: yes Blinding: no (7) Level: 2	0.5 oral glutamine granules vs. placebo (isocaoric, isonitrogenous) 2.0 gm/kg/d protein	NA	NA	NA	NA	46.59 ±12.98 (25)	55.68 ± 17.36 (23)	NA	NA
8) Luo 2008***	Medical Surgical N=44	C.Random: not sure ITT: no Blinding: double (9) Level: 2	0.32 glutamine + IV saline + vs. Nutren + 15% Clinisol (placebo) (isocaoric, isonitrogenous) 1.7 gm/kg/d protein	28 day 1/12 ICU 1/12	28 day 0 /9 ICU 0 /9	NA	NA	NA	NA	8.1 ±0.4 (12)	6.9 ± 0.9 (9)
9) McQuiggan 2008	Shock trauma patients N = 20	C.Random: Not sure ITT: yes Blinding: no (10) Level: 2	0.5 (actual 0.4) Impact + glutasolve via NJ tube (1.3 gm/kg/day protein), bolus with H20 vs. Impact + protein supplements {isonitrogenous,isocaloric, 0.85 gm/kg/day protein}	0/10	2/10 (20)	NA	NA	32 ± 13.6 (10)	39.3 ±33.6 (10)	4.8 ±- 6.7 (10)	10.4 ±6.2 (10)
10) Pattanshetti 2009	Bum ICU patients N=30	C.Random: Not sure ITT: yes Blinding: single (outcomes) (8) Level: 2	Enteral isonitrogenous mixture + 0.5 g/kg/d EN glutamine supplement + 'regular' nutrition vs Enteral isonitrogenous mixture + 'regular' nutrition	0/15	2/15	NA	NA	22.73 ± 9.13	39.73 ± 18.27	NA	NA
11) van Zanten 2014	Mixed, N= 301	C Random: Yes ITT: Yes Blinding: double (12) Level: 1	Glutamine,omega-3, aox enriched EN (experimental product, Nutriciar) vs high-protein EN (Nutrison Advanced Protison-Nutricia)	Hospital 38/152 (25) ICU 30/152 (20) 28 day 31/152 (20) 6 month 53/152 (35)	Hospital 33/149 (22) ICU 29/149 (20) 28 day 25/149 (17) 6 month 42/149 (29)	80/152 (53)	78/149 (52)	38.2 ± 28.9	37.7 ± 27.5	23.7 ± 22.4 (152)	25.6 ± 24.0 (149)
	Trauma subgroup			Hospital 6/55 (11) ICU 5/55 (9) 28 day 4/55 (7) 6 month 8/55 (15)	Hospital 6/54 (11) ICU 6/54 (11) 28 day 2/54 (4) 6 month 59/54 (17)	32/55 (58)	36/54 (67)	44.4 ± 31.2	39.8 ± 25.3	31.3 ± 30.3	32.5 ± 27.5

12) Koksal 2014****	Septic, malnourished ICU patients N=120	C.Random: yes ITT: other Blinding: single (outcomes) (9) Level: 2	30 g/day EN glutamine (Glutamine resource, Nestle) + EN vs EN, no placebo, no supplemental glutamine	NA	NA	NA	NA	NA	NA	NA	NA
13) lamsirisaengt hong 2017	Major bum patients (>20% TBSA) N=20	C.Random: no ITT: no Blinding: no (3) Level: 2	Neomune (25% protein, gln and arg containing) vs blenderized diet (17% protein). Isocaloric, non- isonitrogenous.	Hospital 1/10 (10%)	Hospital 1/10 (10%)	Septic complications 4/10 (40%) Wound Healing (days) 32.3 + 14.3	Septic complications 7/10 (70%) Wound Healing (days) 38.3 + 14.9	35.4 ± 15.2	40.4 ± 15.2	NA	NA
14) Efremov 2017	Mechanically ventilated, critically ill patients undergoing elective cardiac surgery N=40	C.Random: yes ITT: yes Blinding: no (10) Level: 2	25 gm/day glutamine (Nutricomp immune-high calorie 1.33 Kcal/mL,6.7 gm/L protein, 0.2 gm/100 mL omega 3) vs.standard EN (Nutricomp standard- 1 Kcal/mL, 3.8 gm/lL protein, 0.26 gm/100 mL omega 3). PN used to supplement. Non-isocaloric, non- isonitrogenous	Hospital 6/20 (30%)	Hospital 4/20 (20%)	NA	NA	Hospital 30 (25-33)*	Hospital 26 (19-21)*	ICU 11 (7-23)*	ICU 9 (7-11)*
15) Shariatpana hi 2019	Mix ICU adult patients Medical (32) Surgical (24) Trauma (14)	C.Random: no ITT: no Blinding: no (6) Level: 2	Glutamine (0.3 grams/kg/d) + EN vs. placebo (maltodextrin) + EN; both 3 times per day	ICU 7/36 19% (95% Cl:8-33%)	ICU 4/34 12% (95% CI:3-24%)	New sepsis 5.6% (95% Cl; 0– 13.9%)	New sepsis 11.8% (95% Cl, 2.8– 23.5%	NA	NA	10 (8-20)*	13 (7-29)*
16) Nakamura 2020	Mix ICU population Sepsis (42); Cardiac (20); Stroke (23); Cardiopulmonary arrest (6); Post surgery (13); Respiratory failure (23); trauma (2)	C.Random: Yes ITT: Yes Blinding: single (12) Level: 2	Daily 3grams HMB+14 grams arginine+14 grams of glutamine vs. standard EN	28 days 8.7% (4/45)	28 days 13.6% (6/43)	NA	NA	21.9 ±8.8	24.3 ±7.8	5.4 ±3.5	5.8 ±3.8
	Final Femoral Muscle subgroup analysis SOC (24) vs. Intervention (26)			30-day mortality rate 16.8%	30-day mortality rate 19.3%	NA	NA	20.4 ±10.7	19.8 ±12.5	9.1 ±4.4	8.6 ±5.2
	Femoral Muscle Volume by SOFA subgroup			SOFA<10: 0% SOFA>10:	SOFA <10: 0% SOFA>10:	NA	NA	SOFA<10 22.7 ±13.1 SOFA>10	SOFA<10 19.6 ±9.9 SOFA>10	SOFA<10 10.0 ±4.4 SOFA>10	SOFA<10 7.3 ±3.7 SOFA>10
	SOFA <10 (31) vs. SOFA >10 (19)			SOFA>10: 26.5%	SOFA>10: 25.8%			SOFA>10 17.3 ±7.1	SOFA>10 20.1 ±13.4	SOFA>10 7.9 ±4.4	SOFA>10 11.3 ±6.9

C.Random: concealed randomization median (range) EN: enteral nutrition ITT: intent to treat TPN: Total parenteral nutrition \pm () : mean \pm Standard deviation (number) † hospital mortality unless otherwise stated * median and range hence not included in meta-analyses ** data from a subgroup, hence not included in meta-analyses *** data from PN glutamine group not shown here, appears in PN glutamine section ****Reports on mechanical ventilation 28 or 30 day hospital mortality were aggregated as Overall Mortality NA: Not available or not reported

NA: not available

Figure 1. Overall Hospital Mortality

	EN gluta	mine	Contr	ol		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	Year	M-H, Random, 95% Cl
Houdijk	4	41	3	39	3.4%	1.27 [0.30, 5.31]	1998	
Jones	10	26	9	24	13.7%	1.03 [0.50, 2.08]	1999	
Garrel	2	21	12	24	3.6%	0.19 [0.05, 0.76]	2003	← ⊷
Hall	24	179	23	184	24.2%	1.07 [0.63, 1.83]	2003	_
Lou	1	12	0	9	0.7%	2.31 [0.10, 50.85]	2007	
McQuiggan	0	10	2	10	0.8%	0.20 [0.01, 3.70]	2008	←
Pattanshetti	0	15	2	15	0.8%	0.20 [0.01, 3.85]	2009	←
van Zanten	38	152	33	149	41.4%	1.13 [0.75, 1.70]	2014	_
Efremov	6	20	4	20	5.7%	1.50 [0.50, 4.52]	2017	
lamsirisaengthong	1	10	1	10	1.0%	1.00 [0.07, 13.87]	2017	·
Nakamura	4	45	6	43	4.8%	0.64 [0.19, 2.10]	2020	
Total (95% CI)		531		527	100.0%	1.00 [0.77, 1.30]		•
Total events	90		95					
Heterogeneity: Tau ² =	= 0.00; Chi ^z	= 9.93,	df = 10 (l	P = 0.4	5); I² = 0%			
Test for overall effect								0.1 0.2 0.5 1 2 5 10 Favors EN glutamine Favors control

Figure 2. Hospital Mortality, trauma subgroup analysis




Figure 3. Hospital Mortality, burns subgroup

	EN Gluta	mine	Contr	ol		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	Year	M-H, Random, 95% Cl
Garrel	2	21	12	24	67.0%	0.19 [0.05, 0.76]	2003	
Pattanshetti	0	15	2	15	14.6%	0.20 [0.01, 3.85]	2009	• • •
lamsirisaengthong	1	10	1	10	18.4%	1.00 [0.07, 13.87]	2017	
Total (95% CI)		46		49	100.0%	0.26 [0.08, 0.80]		
Total events	3		15					
Heterogeneity: Tau ² =	= 0.00; Chi ^a	²= 1.24,	df = 2 (P	= 0.54)); I² = 0%			0.02 0.1 1 10 50
Test for overall effect	: Z = 2.34 (ł	P = 0.02	9					Favors EN Glutamine Favors Control

Figure 4. Infectious Complications




Figure 5. Infectious Complications: trauma




Figure 6: Hospital LOS




Figure 7. Hospital LOS, burns subgroup analysis

	EN G	Slutamii	ne	C	Control			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	Year	IV, Random, 95% Cl
Zhou	67	4	20	73	6	20	55.1%	-6.00 [-9.16, -2.84]	2003	-8
Peng	46.59	12.98	25	55.68	17.36	23	19.7%	-9.09 [-17.82, -0.36]	2004	
Pattanshetti	22.73	9.13	15	39.73	18.27	15	15.2%	-17.00 [-27.34, -6.66]	2009	-
lamsirisaengthong	35.4	15.2	10	40.4	15.2	10	9.9%	-5.00 [-18.32, 8.32]	2017	
Total (95% CI)			70			68	100.0%	-8.18 [-12.69, -3.67]		•
Heterogeneity: Tau ² =	= 7.00; Cl	hi² = 4.2	28, df =	3 (P = 0	.23); I ≊ =	= 30%				-20 -10 0 10 20
Test for overall effect:	Z = 3.56	(P = 0.	0004)							Favors EN Glutamine Favors Control

Figure 8. Hospital LOS, trauma subgroup analysis

	EN G	ilutami	ine	С	ontrol			Mean Difference		Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	Year	IV, Random, 95% Cl	
Houdijk	32.7	17.1	35	33	23.8	37	16.4%	-0.30 [-9.83, 9.23]	1998		
Brantley	19.5	8.8	31	20.8	11.5	41	67.6%	-1.30 [-5.99, 3.39]	2000		
McQuiggan	32	13.6	10	39.3	33.6	10	2.9%	-7.30 [-29.77, 15.17]	2008	+	+
van Zanten	44.4	31.2	55	39.8	25.3	54	13.1%	4.60 [-6.05, 15.25]	2014		+
Total (95% CI)			131			142	100.0%	-0.54 [-4.40, 3.31]			
Heterogeneity: Tau ² =				= 3 (P =	0.72);	I ^z = 0%				-10 -5 0 5 1	0
Test for overall effect:	Z= 0.27	(P=0).78)							Favours EN Glutamine Favours Control	

Figure 9. ICU LOS, all studies




Figure 10. ICU LOS, trauma subgroup analysis

	EN G	ilutami	ine	C	ontrol			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
McQuiggan	4.8	6.7	10	10.4	6.2	10	78.6%	-5.60 [-11.26, 0.06]	2008	
van Zanten	31.3	30.3	55	32.5	27.5	54	21.4%	-1.20 [-12.06, 9.66]	2014	
Total (95% CI)			65			64	100.0%	-4.66 [-9.68, 0.36]		•
Heterogeneity: Tau² = Test for overall effect:	•		•	= 1 (P =	0.48);	I² = 0%				-100 -50 0 50 100 Favours EN Glutamine Favours Control

Figure 11. Mechanical Ventilation Days

	EN G	EN Glutamine Control						Mean Difference		Mean Difference				
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year		IV, I	Random, 95%	S CI	
Garrel	24	11	16	22	10	19	1.0%	2.00 [-5.02, 9.02]	2003			- -		
Lou	6	1	12	6	1	9	66.0%	0.00 [-0.86, 0.86]	2007					
Koksal	13	6.5	30	14.3	5.4	30	5.4%	-1.30 [-4.32, 1.72]	2014			-		
Nakamura	4.8	2.4	45	5.3	3.8	43	27.7%	-0.50 [-1.83, 0.83]	2020			•		
Total (95% CI)			103			101	100.0%	-0.19 [-0.89, 0.51]						
Heterogeneity: Tau ² = Test for overall effect					P = 0	.73); I²	= 0%			-100 Fav	-50 ours EN Glut	0 amine Favou	50 rs Control	100

References

Included Studies

- 1. Houdijk AP, Rijnsburger ER, Jansen J, Wesdorp RI, Weiss JK, McCamish MA, Teerlink T, Meuwissen SG, Haarman HJ, Thijs LG, van Leeuwen PA. Randomised trial of glutamine-enriched enteral nutrition on infectious morbidity in patients with multiple trauma. Lancet. 1998 Sep 5;352(9130):772-6.
- 2. Jones C, Palmer TE, Griffiths RD. Randomized clinical outcome study of critically ill patients given glutamine-supplemented enteral nutrition. Nutrition. 1999 Feb;15(2):108-15.
- 3. Brantley S, Pierce J: Effects of enteral glutamine on trauma patients. Nutrition in Clinical Practice 2000; 15, S13.
- 4. Hall JC, Dobb G, Hall J, De Sousa R, Brennan L, McCauley R. A prospective randomized trial of enteral glutamine in critical illness. Intensive Care Med. 2003 Oct;29(10):1710-6.
- 5. Garrel D, Patenaude J, Nedelec B, Samson L, Dorais J, Champoux J, D'Elia M, Bernier J. Decreased mortality and infectious morbidity in adult burn patients given enteral glutamine supplements: a prospective, controlled, randomized clinical trial. Crit Care Med. 2003 Oct;31(10):2444-9.
- 6. Zhou YP, Jiang ZM, Sun YH, Wang XR, Ma EL, Wilmore D. The effect of supplemental enteral glutamine on plasma levels, gut function, and outcome in severe burns: a randomized, double-blind, controlled clinical trial. JPEN J Parenter Enteral Nutr. 2003 Jul-Aug;27(4):241-5.
- 7. Peng X, Yan H, You Z, Wang P, Wang S. Effects of enteral supplementation with glutamine granules on intestinal mucosal barrier function in severe burned patients. Burns. 2004 Mar;30(2):135-9.
- Luo M, Bazargan N, Griffith DP, Estivariz CF, Leader LM, Easley KA, Daignault NM, Metabolic effects of enteral versus parenteral alanyl-glutamine dipeptide administration in critically ill patients receiving enteral feeding: a pilot study. Hao L, Meddings JB, Galloway JR, Blumberg JB, Jones DP, Ziegler TR. Clin Nutr. 2008 Apr;27(2):297-306. Epub 2008 Feb 7.
- 9. McQuiggan M, Kozar R, Sailors RM, Ahn C, McKinley B, Moore F. Enteral glutamine during active shock resuscitation is safe and enhances tolerance of enteral feeding. JPEN J Parenter Enteral Nutr 2008;32(1):28-35.]
- 10. Pattanshetti VM, Powar RS, Godhi AS, Metgud SC. Enteral glutamine supplementation reducing infectious morbidity in burns patients: a randomised controlled trial. Indian J Surg. 2009 Aug;71(4):193-7.
- 11. Koksal GM, Erbabacan E, Tunali Y, Karaoren G, Vehid S, Oz H. The effects of intravenous, enteral and combined administration of glutamine on malnutrition in sepsis: a randomized clinical trial. Asia Pac J Clin Nutr. 2014;23(1):34-40.
- 12. van Zanten AR, Sztark F, Kaisers UX, Zielmann S, Felbinger TW, Sablotzki AR, De Waele JJ, Timsit JF, Honing ML, Keh D, Vincent JL, Zazzo JF, Fijn HB, Petit L, Preiser JC, van Horssen PJ, Hofman Z. High-protein enteral nutrition enriched with immune-modulating nutrients vs standard high-protein enteral nutrition and nosocomial infections in the ICU: a randomized clinical trial. JAMA. 2014 Aug 6;312(5):514-24
- 13. Iamsirisaengthong W, Chinaroonchai K, Chuntrasakul C, Roeksomtawin S, Muangman P. Prospective controlled trial to compare immune-enhancing and regular enteral diets to reduce septic complication in major burn patients. Journal of the Medical Association of Thailand. 100 (3 Supplement 2) (pp S121-S125).
- 14. Efremov S, Lomivorotov V, Stoppe C, et al. Standard vs. Calorie-Dense Immune Nutrition in Haemodynamically Compromised Cardiac Patients: A Prospective Randomized Controlled Pilot Study. *Nutrients*. 2017;9(11):1264. Published 2017 Nov 20. doi:10.3390/nu9111264
- 15. Shariatpanahi ZV, Eslamian G, Ardehali SH, Baghestani AR. Effects of Early Enteral Glutamine Supplementation on Intestinal Permeability in Critically III Patients. Indian J Crit Care Med. 2019 Aug;23(8):356-362. doi: 10.5005/jp-journals-10071-23218. PMID: 31485104; PMCID: PMC6709840.
- 16. Nakamura K, Kihata A, Naraba H, Kanda N, Takahashi Y, Sonoo T, Hashimoto H, Morimura N. β-Hydroxy-β-methylbutyrate, Arginine, and Glutamine Complex on Muscle Volume Loss in Critically III Patients: A Randomized Control Trial. JPEN J Parenter Enteral Nutr. 2020 Feb;44(2):205-212. doi: 10.1002/jpen.1607. Epub 2019 May 27. PMID: 31134640.

Excluded Studies	Reasons
Jebb SA, Marcus R, Elia M. A pilot study of oral glutamine supplementation in patients receiving bone marrow transplants. Clin Nutr. 1995 Jun;14(3):162-5.	Transplant/elective surgery patients
Long CL, Nelson KM, DiRienzo DB, Weis JK, Stahl RD, Broussard TD, Theus WL,Clark JA, Pinson TW, Geiger JW, et al. Glutamine supplementation of enteral nutrition: impact on whole body protein kinetics and glucose metabolism in critically ill patients. J Parenter Enteral Nutr. 1995 Nov-Dec;19(6):470-6.	No clinical outcomes
Jensen GL, Miller RH, Talabiska DG, Fish J, Gianferante L. A double-blind, prospective, randomized study of glutamine-enriched compared with standard peptide-based feeding in critically ill patients. Am J Clin Nutr 1996;64(4):615-21.	No clinical outcomes
Fish J, Sporay G, Beyer K, Jones J, Kihara T, Kennedy A, Apovian C, Jensen GL. A prospective randomized study of glutamine-enriched parenteral compared with enteral feeding in postoperative patients. Am J Clin Nutr. 1997 Apr;65(4):977-83.	Surgical patients
Scolapio JS, Camilleri M, Fleming CR, Oenning LV, Burton DD, Sebo TJ, Batts KP, Kelly DG. Effect of growth hormone, glutamine, and diet on adaptation in short-bowel syndrome: a randomized, controlled study. Gastroenterology. 1997 Oct;113(4):1074-81. Comment in: Gastroenterology. 1997 Oct;113(4):1402-5.	Crossover design
Anderson PM, Ramsay NK, Shu XO, Rydholm N, Rogosheske J, Nicklow R, Weisdorf DJ, Skubitz KM. Effect of low-dose oral glutamine on painful stomatitis during bone marrow transplantation. Bone Marrow Transplant. 1998 Aug;22(4):339-44.	Surgical patients
Anderson PM, Schroeder G, Skubitz KM. Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy. Cancer. 1998 Oct 1;83(7):1433-9.	Pediatric patients
Den Hond E, Hiele M, Peeters M, Ghoos Y, Rutgeerts P. Effect of long-term oral glutamine supplements on small intestinal permeability in patients with Crohn's disease JPEN J Parenter Enteral Nutr. 1999 Jan-Feb;23(1):7-11	Not ICU patients
Schloerb PR, Skikne BS. Oral and parenteral glutamine in bone marrow transplantation: a randomized, double-blind study. JPEN J Parenter Enteral Nutr. 1999 May-Jun;23(3):117-22.	Surgical patients
Scolapio JS. Effect of growth hormone, glutamine, and diet on body composition in short bowel syndrome: a randomized, controlled study. JPEN J Parenter Enteral Nutr. 1999 Nov-Dec;23(6):309-12; discussion 312-3.	Crossover design
Zhou Y, Jiang Z, Sun Y. Gu an zuo an shuang zuo gai shan zhong du shao shang huan zhe chang zhan mo tong tou xing de yan jiu. National Medical Journal of China. 1999;79(11):825.	Earlier study of Zhou 2003 that is included
Jackson NC, Carroll PV, Russell-Jones DL, Sönksen PH, Treacher DF, Umpleby AM. Effects of glutamine supplementation, GH, and IGF-I on glutamine metabolism in critically ill patients. Am J Physiol Endocrinol Metab. 2000 Feb;278(2):E226-33.	Surgical patients; No clinical outcomes
Szkudlarek J, Jeppesen PB, Mortensen PB. Effect of high dose growth hormone with glutamine and no change in diet on intestinal absorption in short bowel patients: a randomised, double blind, crossover, placebo controlled study. Gut. 2000 Aug;47(2):199-205.	Crossover design
Chen G, Xie W, Jiang H. [Clinical observation of the protective effect of oral feeding of glutamine granules on intestinal mucous membrane]. Zhonghua Shao Shang Za Zhi. 2001 Aug;17(4):210-1. Chinese. PubMed PMID: 11876941.	No clinical outcomes
Scolapio JS, McGreevy K, Tennyson GS, Burnett OL. Effect of glutamine in short-bowel syndrome. Clin Nutr. 2001 Aug;20(4):319-23.	Crossover design
Velasco N, Hernandez G, Wainstein C et al. Influence of polymeric enteral nutrition supplemented with different doses of glutamine on gut permeability in critically ill patients. Nutrition 2001;17:907-11.	No clinical outcomes. Duplicate of Houdjik
Boelens PG, Houdijk AP, Fonk JC et al. Glutamine-Enriched Enteral Nutrition Increases HLA-DR Expression on Monocytes of Trauma Patients. J Nutr 2002:2580-6.	No clinical outcomes
Novak F, Heyland DK, Avenell A, Drover JW, Su X. Glutamine supplementation in serious illness: a systematic review of the Evidence. Crit Care Med. 2002 Sep;30(9):2022-9.	Systematic review

Fläring UB, Rooyackers OE, Wernerman J, Hammarqvist F. Glutamine attenuates post-traumatic glutathione depletion in human muscle. Clin Sci (Lond). 2003 Mar;104(3):275-82	Elective surgery patients
García-de-Lorenzo A, Zarazaga A, García-Luna PP, Gonzalez-Huix F, López-Martínez J, Miján A, Quecedo L, Casimiro C, Usán L, del Llano J. Clinical evidence for enteral nutritional support with glutamine: a systematic review. Nutrition. 2003 Sep;19(9):805-11.	Systematic review
Boelens PG, Houdijk AP, Fonk JC, Puyana JC, Haarman HJ, von Blomberg-van der Flier ME, van Leeuwen PA. Glutamine-enriched enteral nutrition increases in vitro interferon-gamma production but does not influence the in vivo specific antibody response to KLH after severe trauma. A prospective, double blind, randomized clinical study. Clin Nutr. 2004 Jun;23(3):391-400.	Duplicate of Houdijk
Falcao de Arruda IS, de Aguilar-Nascimento JE. Benefits of early enteral nutrition with glutamine and probiotics in brain injury patients. Clin Sci (Lond) 2004;106(3):287-92.	Includes probiotics
Peng X, Yan H, You Z, Wang P, Wang S. Clinical and protein metabolic efficacy of glutamine granules-supplemented enteral nutrition in severely burned patients. Burns 2005;31(3):342-6.	Duplicate of Peng 2004
"Peng X, Yan H, You Z, Wang P, Wang S. Glutamine granule-supplemented enteral nutrition maintains immunological function in severely burned patients. Burns. 2006 Aug;32(5):589-93. Epub 2006 May 24. PubMed PMID: 16725264."	Duplicate of Peng 2004
Guo GH, Deng ZY, Wang YX, Xing JJ, Peng Y, Li GH. [Effects of glutamine enriched enteral feeding on immunoregulation in burn patients]. Zhonghua Shao Shang Za Zhi. 2007 Dec;23(6):406-8. Chinese. PubMed PMID: 18457248.	No clinical outcomes
Kuhls DA, Rathmacher JA, Musngi MD, Frisch DA, Nielson J, Barber A, MacIntyre AD, Coates JE, Fildes JJ. Beta-hydroxy-beta-methylbutyrate supplementation in critically ill trauma patients. J Trauma. 2007 Jan;62(1):125-31; discussion 131-2.	Too many interventions
Spindler-Vesel A, Bengmark S, Vovk I, Cerovic O, Kompan L. Synbiotics, prebiotics, glutamine, or peptide in early enteral nutrition: a randomized study in trauma patients. JPEN J Parenter Enteral Nutr. 2007 Mar-Apr;31(2):119-26.	Too many interventions
Beale RJ, Sherry T, Lei K, Campbell-Stephen L, McCook J, Smith J, Venetz W, Alteheld B, Stehle P, Schneider H. Early enteral supplementation with key pharmaconutrients improves Sequential Organ Failure Assessment score in critically ill patients with sepsis: outcome of a randomized, controlled, double- blind trial. Crit Care Med 2008;36(1):131-44.	Patients received glutamine dipeptides, vit C and E, carotene, selenium, zinc, and butyrate in combination with an immunonutrition formula
Jiang H, Chen W, Hu W, Cai B, Liao RJ. [The impact of glutamine-enhanced enteral nutrition on clinical outcome of patients with critical illness: a systematic review of randomized controlled trials]. Zhonghua Shao Shang Za Zhi. 2009 Oct;25(5):325-30. Review. Chinese. PubMed PMID: 19951553.	Systematic review
Han YY, Lai SL, Ko WJ, Chou CH, Lai HS. Effects of fish oil on inflammatory modulation in surgical intensive care unit patients. Nutr Clin Pract. 2012 Feb;27(1):91-8. Epub 2012 Jan 6. PubMed PMID: 22227725.	Elective surgery patients
Cavalcante AA, Campelo MW, de Vasconcelos MP, Ferreira CM, Guimarães SB,Garcia JH, de Vasconcelos PR. Enteral nutrition supplemented with I- glutamine in patients with systemic inflammatory response syndrome due to pulmonary infection. Nutrition. 2012 Apr;28(4):397-402. Epub 2011 Nov 4. PubMed PMID: 22055478.	No clinical outcomes; Crossover design
Wang X, Dong Y, Han X, Qi X-Q, Huang C-G, Hou L. (2013) Nutritional Support for Patients Sustaining Traumatic Brain Injury: A Systematic Review and Meta-Analysis of Prospective Studies. PLoS ONE. 8(3): e58838.	Meta-analysis
Han W. Sun J. Han R. Wang Y. Yi Q. Hua L. Tian F. Application of enteral nutrition support with different doses of glutamine in elderly critically ill patients. Chin J Clin Nutr 2014;22(3):149-153.	No clinical outcomes
"Kibor DK, Nyaim OE, Wanjeri K. Effects of enteral glutamine supplementation on reduction of infection in adult patients with severe burns. East Afr Med J. 2014 Jan;91(1):33-6."	No clinical outcomes
Han W., Sun J., Han R., Wang Y., Yi Q., Hua L., Tian F. Application of enteral nutrition support with different doses of glutamine in elderly critically ill patients. Chinese Journal of Clinical Nutrition. 2014 Jun;22(3):149-153, 2014.	No clinical outcomes

Azman M, Mohd Yunus MR, Sulaiman S, Syed Omar SN. Enteral glutamine supplementation in surgical patients with head and neck malignancy: A randomized controlled trial. Head Neck. 2015 Dec;37(12):1799-807. doi: 10.1002/hed.23839.	Surgical patients
Hofman Z, Swinkels S, van Zanten ARH. Glutamine, fish oil and antioxidants in critical illness: MetaPlus trial post hoc safety analysis. Ann Int Care. 2016:6;119.	Post hoc analysis, no new relevant outcomes
Vijey Aanandhi M, John M.R. Enteral oral glutamine supplementation in patients following surgery and accidental injury. Asian J Pharm and Clin Res. 2017 March;10(3):477-479	Surgical patients
Shariatpanahi M, Raghunath M, Deepika G, Jakkampudi A, Murthy HVV, Rao GV, Reddy DN, Talukdar R. Efficacy of enteral glutamine supplementation in patients with severe and predicted severe acute pancreatitis- A randomized controlled trial. Indian J Gastroenterol. 2019 Aug;38(4):338-347. doi: 10.1007/s12664-019-00962-7. Epub 2019 Oct 14. PMID: 31612309.	Not ICU patients